Safety Policies & Visitor Guidelines |
Appointments & Scheduling |
COVID Symptoms |
Schedule a COVID vaccine or booster appointment:
Log in to myPennMedicine or call us 8am to 5pm, Monday through Friday, at 267-758-4902.
Sees patients age 18 and up
Sees patients age 18 and up
Recognized by America's Top Doctors, 2007, 2008, 2010, 2012 - 2018
Recognized by Best Doctors in America 2005 - 2018
Recognized annually in Philadelphia magazine's Top Docs issue from 2005 through 2021
Perelman Center for Advanced Medicine
South Pavilion, 2nd Floor
3400 Civic Center Boulevard
Philadelphia, PA 19104
Spruce Building, 1st Floor
801 Spruce Street
Philadelphia, PA 19107
The Patient Satisfaction Rating is an average of all responses to the care provider related question shown above from our internal platform, PMX Feedback. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.
Yin Y, Rodriguez JL, Li N, Thokala R, Nasrallah MP, Hu L, Zhang L, Zhang JV, Logun MT, Kainth D, Haddad L, Zhao Y, Wu T, Johns EX, Long Y, Liang H, Qi J, Zhang X, Binder ZA, Lin Z, O'Rourke DM: Locally secreted BiTEs complement CAR T cells by enhancing killing of antigen heterogeneous solid tumors. Mol. Ther. : S1525-0016(22)00309-4,2022.
Fathi Kazerooni A, Saxena S, Toorens E, Tu D, Bashyam V, Akbari H, Mamourian E, Sako C, Koumenis C, Verginadis I, Verma R, Shinohara RT, Desai AS, Lustig RA, Brem S, Mohan S, Bagley SJ, Ganguly T, O'Rourke DM, Bakas S, Nasrallah MP, Davatzikos C: Clinical measures, radiomics, and genomics offer synergistic value in AI-based prediction of overall survival in patients with glioblastoma. Sci Rep. 12 (1): 8784,2022.
Alanio C, Binder ZA, Chang RB, Nasrallah MP, Delman D, Li JH, Tang OY, Zhang LY, Zhang JV, Wherry EJ, O'Rourke DM, Beatty GL.: Immunological features in de novo and recurrent glioblastoma associate with survival outcomes. Cancer Immunol Res. : canimm.CIR-21-1050-E.2021,2022.
Reed-Guy L, Desai AS, Phillips RE, Croteau D, Albright K, O'Neill M, Brem S, O'Rourke DM, Amankulor NM, Bagley SJ: Risk of intracranial hemorrhage with direct oral anticoagulants versus low molecular weight heparin in glioblastoma: A retrospective cohort study. Neuro Oncol. : noac125,2022.
Tang OY, Tian L, Yoder T, Xu R, Kulikovskaya I, Gupta M, Melenhorst JJ, Lacey SF, O'Rourke DM*, Binder ZA*: PD1 Expression in EGFRvIII-Directed CAR T Cell Infusion Product for Glioblastoma Is Associated with Clinical Response. Front. Immunol. 13 : 872756,2022.
Durgin JS, Thokala R, Johnson L, Song E, Leferovich J, Bhoj V, Ghassemi S, Milone M, Binder Z, O'Rourke DM, O'Connor RS: Enhancing CAR T function with the engineered secretion of C. perfringens neuraminidase. Mol. Ther. 30 (3): 1201-1214,2022.
Nazem A, Guiry SC, Pourfathi M, Ware JB, Anderson H, Iyer SK, Moon BF, Fan Y, Witschey WR, Rizi R, Bagley SJ, Desai A, O'Rourke DM, Brem S, Nasrallah M, Nabavizadeh A.: MR susceptibility imaging for detection of tumor-associated macrophages in glioblastoma. J Neurooncol. 156 (3): 645-653.,2022.
R Thokala, ZA Binder, Y Yin, L Zhang, JV Zhang, DY Zhang, MC Milone, Ming GL, Song H, DM O'Rourke: High Affinity Chimeric Antigen Receptor with Cross-Reactive scFv to Clinically Relevant EGFR Oncogenic Isoforms Front Oncol 11 : 664236,2021.
Akbari H, Kazerooni AF, Ware JB, Mamourian E, Anderson H, Guiry S, Sako C, Raymond C, Yao J, Brem S, O'Rourke DM, Desai AS, Bagley SJ, Ellingson BM, Davatzikos C, Nabavizadeh A: Quantification of tumor microenvironment acidity in glioblastoma using principal component analysis of dynamic susceptibility contrast enhanced MR imaging. Sci Rep. 11 (1): 2021.
Durgin JS, Henderson F Jr, Nasrallah MP, Mohan S, Wang S, Lacey SF, Melenhorst JJ, Desai AS, Lee JYK, Maus MV, June CH, Brem S, O'Connor RS, Binder Z, O'Rourke DM: Case Report: Prolonged Survival Following EGFRvIII CAR T Cell Treatment for Recurrent Glioblastoma Front Oncol 7 (11): 669071,2021.
HUP - 15th floor, South Perelman3401 Civic Center Boulevard
Patient appointments: 800-789-7366